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Edited by Horst FeldmannAbstract Receptor interacting protein (RIP) is recruited to
tumor necrosis factor-a receptor 1 (TNFR1) complex upon
stimulation and plays a crucial role in the receptor-mediated NF-
jB activation. Among the components of the TNFR1 complex
are proteins that possess ubiquitin-protein isopeptide ligase (E3)
activities, such as TNFR1-associated factor 2 (TRAF2), cellular
inhibitor of apoptosis proteins (c-IAPs) namely, c-IAP1 and c-
IAP2. Here, we showed that ectopically expressed RIP is
ubiquitinated, and either the intermediate or death domain of
RIP is required for this modiﬁcation. Expression of c-IAP1 and
c-IAP2 decreased the steady-state level of RIP, which was
blocked by inhibition of the 26S proteasome. RIP degradation
requires intact c-IAP2 containing the RING domain. Our in
vitro ubiquitination assay revealed that while TRAF2 had no
eﬀect, both c-IAP1 and c-IAP2-mediated RIP ubiquitination
with similar eﬃciency, indicating that c-IAPs can function as E3
toward RIP.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumor necrosis factor-a receptor 1 (TNFR1) mediates a
variety of signals, including activation of transcription factor
NF-jB, c-Jun N-terminal kinase (JNK) as well as induction of
apoptosis [1,2]. Triggering of TNFR1 with trimeric TNFa
leads to the recruitment of TNFR1-associated death domain
(TRADD) protein to the receptor cytoplasmic death domain
(DD) [3]. TRADD subsequently serves as a platform for re-
cruiting a group of signaling proteins to the receptor complex.
These include Fas-associated death domain (FADD) protein,
TNFR1-associated factor 2 (TRAF2) and receptor interacting* Corresponding author. Fax: +82-2-312-2242.
E-mail address: thlee@yonsei.ac.kr (T.H. Lee).
Abbreviations: TNFR1, tumor necrosis factor-a receptor 1; JNK, c-Jun
N-terminal kinase; TRADD, TNFR1-associated death domain;
FADD, Fas-associated death domain protein; TRAF2, TNFR1-
associated factor 2; RIP, receptor interacting protein; DD, death
domain; c-IAP, cellular inhibitor of apoptosis protein; BIR, baculo-
virus IAP repeat; E1, ubiquitin-activating enzyme; E2, ubiquitin-
conjugating enzyme; E3, ubiquitin-protein isopeptide ligase
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doi:10.1016/j.febslet.2004.04.021protein (RIP) [4,5]. While the association of FADD with
TRADD initiates the apoptosis program by recruiting pro-
caspase-8, the recruitment of RIP and TRAF2 elicits activa-
tion of NF-jB and JNK, respectively [4,6,7]. The crucial role
of RIP in the activation of NF-jB has been demonstrated in
RIP knock-out mice, as cells derived from RIP-deﬁcient mice
are unable to activate NF-jB following TNFa treatment [8].
RIP consists of three distinct domains: the N-terminal ser-
ine/threonine protein kinase domain (KD), an intermediate
domain (ID), and a C-terminal DD. The RIP KD is dispens-
able for NF-jB activation, whereas the ID mediates the acti-
vation upon RIP recruitment to the TNFR1 complex through
the DD-mediated interaction with the DD of TRADD or with
the DD of TNFR1. Overexpression of the ID alone suﬃces to
activate NF-jB, but expression of DD alone blocks NF-jB
activation and induces apoptosis [5,6].
The proteins that bind to RIP include TRAF2, which in turn
interacts with cellular inhibitor of apoptosis proteins (c-IAPs),
c-IAP1 (HIAP2/MIHB) and c-IAP2 (HIAP1/MIHC) [9,10].
Structurally, the c-IAPs contain three baculovirus IAP repeats
(BIRs) and a C-terminal RING domain. These c-IAPs can di-
rectly inhibit caspase-3 and -7 through their BIR domains and
intermediary linker region [11,12]. The RING domains of c-
IAPs have been shown to possess ubiquitin-protein isopeptide
ligase (E3) activities [13–17]. Protein polyubiquitination re-
quires the cooperation of three enzymes: the ubiquitin-
activating enzyme (E1), a ubiquitin-conjugating enzyme (E2)
and a E3, which transfers the activated ubiquitin from E2 to
lysine residues of the bound substrate. Substrate speciﬁcity is
determined mainly by the E3 enzymes. Once the multiubiquitin
chain is assembled on a protein substrate, the target protein is
recognized and degraded by the 26S proteasome [18,19]. Sub-
strates that are targeted by E3 enzymatic activities of c-IAPs
include themselves [13,14] and proteins implicated in the reg-
ulation of apoptosis and NF-jB activation [15–17]. For ex-
ample, c-IAP1 mediates the ubiquitination of TRAF2 [15] and
NEMO (IKK-c) [16]. A recent report indicates that both
c-IAP1 and c-IAP2 are E3 for mitochondrial cell death inducer
Smac/DIABLO [17]. In addition, it was also reported that
c-IAP2 mediates in vitro mono-ubiquitination of caspase-3 and
-7 [14]. In light of the complexity of proteins recruited to the
TNFR1 in conjunction with the c-IAPs, it is reasonable to as-
sume that a protein(s) constituting the receptor complex other
than TRAF2 can be ubiquitinated by c-IAPs. In fact, it has
been shown that upon recruitment to the TNFR1 complex,
some species of RIP undergo covalent modiﬁcation and exhibitblished by Elsevier B.V. All rights reserved.
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ubiquitinated [20–24]. However, how RIP is ubiquitinated has
not been studied. Here, we present evidence that RIP is a target
of the E3 activities of c-IAPs in vitro. Our data provide clues to
understanding the mechanism of how RIP is ubiquitinated and
degraded upon recruitment to the TNFR1 complex.2. Materials and methods
2.1. Cell culture and reagents
Culture media were purchased from Life Technologies Inc. HEK293
cells were maintained in Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% fetal bovine serum at 37 C with 5% CO2. N-
Acetylleucylleucylnorleucinal (ALLN) and MG132 that were used at
the respective concentration of 10 lg/ml and 10 lM were purchased
from Calbiochem. Antibodies were sourced as follows: monoclonal
anti-RIP Ab was from BD Pharmingen, anti-Flag M2 monoclonal Ab
from Sigma, anti-ubiquitin Ab from Zymed, anti-HA Ab from Santa
Cruz, anti-c-IAP2 Ab from R&D systems and anti-GST Ab from
Amersham.
2.2. Plasmid constructs
Expression plasmids for HA-tagged murine RIP and its deletion
mutants were provided by Dr. E.-J. Choi (Korea University, Korea)
[25]. The cDNA for Flag-tagged RIP and GST-fused RIP is of hu-
man origin. The cDNAs for c-IAP1, c-IAP2 and its deletions were
PCR-ampliﬁed using the cDNA templates originated from pcDNA-
myc-c-IAP1 and -c-IAP2 [12, a kind gift of J.C. Reed] and cloned
downstream of the sequence encoding Flag epitope of pRK5 plasmid.
The amino acid residues present in the c-IAP2 and its deletion con-
structs are as follows: c-IAP2, which is designated as C2 in Fig. 4,
1–604; C2DR, 1–552; C2C, 324–604; C2CDR, 324–552; R, 553–604. To
generate GST-fusion constructs, the cDNAs encoding full-length RIP,
c-IAP1, and c-IAP2 were cloned downstream of GST-coding sequence
in pGEX-5X (Clontech).
2.3. Transfection, immunoprecipitation and Western blot analysis
HEK293 cells were seeded in 6-cm dishes and the following day,
transfection was carried out by the CaPO4-DNA precipitation method
using N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid buﬀer. Af-
ter 16 h, cells were lysed in buﬀer containing 50 mM Tris–HCl (pH
7.4), 150 mM NaCl, 1 mM EDTA, 0.2 mM phenylmethanesulfonyl
ﬂuoride, 1.0% Triton X-100, protease inhibitor cocktail (Sigma) and 10
lMMG132. Cell lysates were incubated with the appropriate Ab for 2
h at 4 C and further incubated with protein-G agarose beads (Sigma)
for 2 h at 4 C. The immune complexes were washed extensively with
the lysis buﬀer for several times. Two times sample loading buﬀer was
added to immune complexes and boiled, and the eluted proteins were
separated by SDS–PAGE. Then, proteins were transferred to nitro-
cellulose membrane (Bio-Rad) and visualized by Western blotting with
the enhanced chemiluminescence reagents (Amersham Pharmacia).
2.4. Expression and puriﬁcation of recombinant proteins
Six-His-tagged yeast Uba1 (E1) and human UbcH5A (E2) [26, a
kind gift from J.W. Conaway] were expressed in Escherichia coli strain
BL21 (DE3) and puriﬁed by Ni2þ–agarose beads (Qiagen). Ubiquitin
containing a six-His tag and a protein kinase C recognition site (a kind
gift from Z.Q. Pan) was puriﬁed as described [27]. Integrity of the
prepared recombinant proteins has been conﬁrmed and described [28].
GST-fused proteins were expressed in E. coli BL21 by adding 0.1 mM
IPTG for 2 h and puriﬁed using glutathione–Sepharose (Pharmacia
Biotech) according to the manufacturer’s instructions. For in vitro
ubiquitination assay, Flag-RIP was translated in vitro in rabbit retic-
ulocyte lysate with a SP6 Quick Coupled Transcription/Translation
System (Promega). Five in vitro translation reactions were performed
and pooled for immunoprecipitation. Lysis buﬀer was added to these
reactions and incubated with anti-Flag M2 Ab-coupled agarose beads
(Sigma) at 4 C for 4 h to immunoprecipitate Flag-RIP. After extensive
washing of the beads with lysis buﬀer, bound RIP protein was eluted
with the lysis buﬀer without detergent containing 0.3 mg/ml Flag
peptide. The eluted Flag-RIP was used as substrate for in vitro ubiq-
uitination reaction.2.5. In vitro ubiquitination assay
GST-RIP expressed in bacteria or Flag-RIP synthesized by in vitro
translation was puriﬁed and used as substrate for in vitro ubiquitina-
tion assay. In some experiments, Flag-c-IAP2 or Flag-TRAF2 were
immunoprecipitated by Flag Ab agarose from lysates of transfected
293 cells (107 cells) and used as E3 enzymes in this bead bound form.
These collected beads were washed twice with ubiquitination reaction
buﬀer prior to the reaction. The ubiquitination assay was carried out in
ubiquitination buﬀer (50 mM Tris, pH 7.5, 2 mM ATP, 2.5 mM
MgCl2, 0.5 mM dithiothreitol and 0.05% NP-40) containing yeast E1
(50 ng), E2 (200 ng) and His6-ubiquitin (0.8 lg) in a total volume of 30
ll. The mixture was incubated at 30 C for 1 h where in experiments
using bead bound substrates, gentle agitation was given to keep beads
in suspension. The reactions were terminated with sample loading
buﬀer and run on SDS–PAGE gels. Higher molecular ladder of
ubiquitinated proteins was visualized by performing immunoblot
analysis with anti-RIP Ab or anti-c-IAP2 Ab.3. Results and discussion
3.1. Detection of ubiquitinated species of RIP
293 cells were transiently transfected with plasmid encoding
HA epitope-tagged RIP (HA-RIP). To block the apoptotic
process caused by RIP overexpression, caspase inhibitor CrmA
expression plasmid was cotransfected. Immunoblot analysis
using an anti-HA Ab revealed that cells transfected with both
HA-RIP and CrmA expression plasmids produced higher
amount of HA-RIP and a number of slow migrating immu-
noreactive bands, compared to cells transfected with the RIP
expression vector alone (Fig. 1A). This ladder-like appearance
of RIP is characteristic of ubiquitinated proteins. To conﬁrm
that RIP is ubiquitinated, immunoprecipitated RIP was ana-
lyzed by Western blot using the anti-ubiquitin Ab. To facilitate
the detection of the ubiquitinated RIP, we also analyzed the
immunoprecipitated RIP prepared from 293 cells coexpressing
Flag-ubiquitin in the presence of CrmA. As shown in Fig. 1B,
the precipitated RIP contained proteins reactive to ubiquitin
Ab, which increased when Flag-ubiquitin was coexpressed. The
same blot reprobed with anti-Flag Ab exhibited strong Flag Ab
reactive products with smeared appearance above the band
corresponding to RIP in the sample coexpressing Flag-ubiq-
uitin (Fig. 1B, right panel). Fig. 1C shows that anti-RIP Ab is
able to detect ubiquitinated RIP even without the coexpression
of CrmA, and its steady-state expression level is enhanced by
the treatment of 26S proteasome inhibitors (ALLN and
MG132), indicating that the ubiquitinated RIP undergoes
proteasome-mediated degradation.3.2. RIP is ubiquitinated in the ID and DD region
To determine the regions required for ubiquitination, we
expressed several deletion mutant proteins of RIP (HA-tagged)
in 293 cells along with Flag-ubiquitin and CrmA (Fig. 2A).
The expression of each deletion protein was conﬁrmed with
Western blot analysis using the anti-HA Ab (Fig. 2B, upper
panel). After immunoprecipitating the expressed RIP proteins
with HA Ab, the ubiquitinated products were analyzed by
immunoblotting with Flag Ab (Fig. 2B, lower panel). While the
KD did not produce ubiquitinated products, the deletion
protein containing the ID and DD exhibited abundant amount
of ubiquitinated products like the wild-type (lanes 3 and 4
Fig. 2B). The ubiquitinated species were not clearly detectable
in the immunoprecipitated samples of the ID and DD. How-
ever, the ID was consistently expressed at a low level, pre-
Fig. 1. RIP undergoes ubiquitination. (A) 293 cells were transfected with expression plasmids encoding HA-RIP alone or with CrmA. 16 h later, cell
lysates were prepared and analyzed by immunoblotting with anti-HA Ab. Higher molecular weight products above RIP are indicated by asterisk (ns,
non-speciﬁc). (B) 293 cells were transfected with HA-RIP plasmid alone or together with Flag-ubiquitin plasmid. Lysates were immunoprecipitated
with anti-HA Ab and immunoblotted with either anti-ubiquitin Ab or anti-Flag Ab. Ubiquitin moieties attached to RIP are indicated by (Ub)n. (Ig-
H, immunoglobulin heavy chain; Ig-L, light chain). (C) Cells transfected with HA-RIP plasmid were treated with proteasome inhibitors, ALLN and
MG132, 4 h prior to cell lysate preparation. Cell lysates were immunoblotted with anti-RIP Ab.
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lane 7 in Fig. 3B). In addition, higher molecular weight
products of the DD proteins were also faintly detected in theFig. 2. ID and DD are required for RIP ubiquitination. (A) Schematic
representation of RIP and its deletion constructs. KD, ID and DD are
indicated. (B) Western blot analysis of the expressed HA-RIP and its
deletion mutants. 293 cells were transfected with the indicated plasmids
and cell lysates were prepared and processed for immunoblotting with
anti-HA Ab (upper). The same lysates were immunoprecipitated with
anti-HA Ab and immunoblotted with anti-Flag Ab to detect Flag-
ubiquitin bound to HA fusion proteins (lower). Reference molecular
weight markers are the same as indicated in Fig. 1A.cell lysates as well as in the immunoprecipitated preparations
(lane 6). When ID and DD were linked to the KD, the re-
sulting KD-ID and KD-DD were ubiquitinated as eﬃciently
as the full-length RIP (lanes 8 and 9). Since the KD alone was
not ubiquitinated, cellular ubiquitination machinery may tar-
get the ID or DD region of RIP for ubiquitination.
3.3. Expression of c-IAP2 decreased the steady-state level of
RIP, which correlates with ubiquitination
During TNFR1 signaling, RIP is recruited to the receptor
complex along with TRAF2, c-IAP1 and c-IAP2, those which
possess E3 activities [13–17,29,30]. Previous reports have
mentioned that within the receptor complex, RIP undergoes
rapid and transient covalent modiﬁcation, which has been
shown to be ubiquitination [23,24]. Having hypothesized that
RIP is a target of an E3 enzyme recruited to the receptor
complex, we tested whether c-IAP2 has any eﬀect on RIP ex-
pression. RIP was cotransfected with diﬀerent amounts of c-
IAP2 expression plasmids in 293 cells and cell lysates from
these transfectants were examined for the level of RIP by im-
munoblotting with anti-RIP Ab. As shown in Fig. 3A, the
expression of c-IAP2 dose-dependently reduced the level of
RIP and the degradation was blocked by the treatment of cells
with ALLN and MG132, showing that 26S proteasome is in-
volved in the degradation of RIP induced by c-IAP2. The
breakdown of RIP by c-IAP2 was also conﬁrmed in HeLa cells
(data not shown). The functional consequence of dose-
dependent RIP degradation by c-IAP2 was conﬁrmed by
concomitant decrease of NF-jB activation induced by RIP
expression (Fig. 3A, right panel). In addition, we observed that
while KD was not degraded, the ID-DD, ID and DD proteins
that can be ubiquitinated were eﬃciently degraded by coex-
pression of c-IAP2, demonstrating that breakdown of RIP and
its deletion derivatives by c-IAP2 correlates with their ubiq-
uitination (Fig. 3B).
3.4. RIP breakdown requires intact c-IAP2 protein
To delineate the structural requirement responsible for the c-
IAP2-mediated RIP destabilization, we constructed various c-
IAP2 deletion mutants (Fig. 4A) and tested whether they
mediate RIP destabilization. Fig. 4B shows that RING do-
main-deleted c-IAP2 mutant proteins (C2DR and C2CDR)
failed to degrade RIP. It has been reported that the RING
Fig. 3. Expression of c-IAP2 dose-dependently induces the degradation
of RIP. (A) Subconﬂuent 293 cells on 6-well-plates were transfected
with HA-RIP and the indicated amounts (lg) of Flag-c-IAP2 plas-
mids. After transfection (16 h), the cell lysates were analyzed by im-
munoblotting with anti-RIP Ab and anti-Flag Ab. In other set of
experiments, the transfected cells were treated with 26S proteasome
inhibitors, 10 lg/ml ALLN and 10 lM MG132 for 4 h. Then, cell
lysates were prepared and the level of RIP was examined by immu-
noblotting with anti-HA Ab. 293 cells were transiently transfected with
0.5 lg of HA-RIP, the indicated amounts of Flag-c-IAP2 and 0.2 lg of
jB-luciferase reporter plasmid, which contains two NF-jB binding
elements derived from the promoter region of c-IAP2 gene [31]. 18 h
after transfection, luciferase activities from lysates were measured.
Values are representative of three independent experiments. (B) 293
cells expressing each indicated HA-RIP deletion construct together
with or without Flag-c-IAP2 were processed for Western blot analysis
to detect the level of expression of RIP proteins with anti-HA Ab
(upper) and of c-IAP2 with anti-Flag Ab (lower).
Fig. 4. RIP degradation by c-IAP2 requires intact full-length c-IAP2 in
vivo. (A) Schematic representation of c-IAP2 and its deletion con-
structs. Indicated are domains of c-IAP2. (B) 293 cells were cotrans-
fected with HA-RIP and various Flag-tagged c-IAP2 deletion
constructs as well as Flag-c-IAP1 as indicated. Cell lysates were pre-
pared, and protein expression levels were analyzed by immunoblotting
with anti-Flag Ab (upper) and by anti-RIP Ab (lower).
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the RING alone can promote self-ubiquitination as well as
mono-ubiquitination of caspase-7 in vitro [14]. However, the
RING domain (R) protein as well as the BIR-deleted protein
(C2C) also failed to degrade RIP, presumably due to the lack
of the region of c-IAP2 to recruit the substrate RIP and other
regulatory proteins. Our observations indicate that RIP deg-
radation by c-IAP2 is RING domain-dependent and that the
BIR domain of c-IAP2 is indispensable for RIP degradation in
vivo. Consistent with our results, it has been recently reported
that in the context of c-IAPs-dependent ubiquitination and
degradation of Smac/DIABLO, the BIR domains of c-IAPs
are required for speciﬁc interaction with Smac/DIABLO [17].
Lane 7 of Fig. 4B shows that in addition to c-IAP2, c-IAP1
promoted RIP degradation.
3.5. c-IAP1 and c-IAP2 ubiquitinate RIP in vitro
To examine whether c-IAP2 ubiquitinates RIP directly, in
vitro ubiquitination assay was performed. Recombinant GST-
RIP was incubated with E1 (His-tagged yeast Uba1), E2 (His-
tagged human UbcH5A) and His-ubiquitin in the absence orpresence of puriﬁed c-IAP2 proteins. Flag-tagged full-length c-
IAP2 (C2) and its RING deletion mutant (C2DR) were ex-
pressed in 293 cells and aﬃnity-puriﬁed using anti-Flag M2
Ab-coupled agarose beads. The reaction products were re-
solved on SDS–PAGE and probed with anti-RIP Ab or with
anti-c-IAP2 Ab. The results showed that the intact c-IAP2
(designated as C2 in Fig. 5A) promoted the formation of
higher molecular ladder of GST-RIP protein, an indication of
ubiquitination, only in the presence of E1 and E2 (lane 6, left
panel Fig. 5A), however no such modiﬁcation was observed
with the C2DR (lane 5, left panel), indicating that the RING
domain is essential for E3 activity of c-IAP2. The addition of
E1 and E2 without functional E3 enzyme produced shifted
bands which appeared to be mono- and di-ubiquitinated forms
of GST-RIP (lane 2 and 5, left panel). At the moment we could
not evaluate what causes this modiﬁcation. When blotted with
anti-c-IAP2 Ab, higher molecular weight species which are
indicative of self-ubiquitinated products of Flag-c-IAP2 were
detected in the reaction performed with the intact c-IAP2, but
not with the RING-deleted c-IAP2 (right panel, Fig. 5A).
To exclude the possibility that other cellular proteins co-
precipitated with c-IAP2 from the transfected 293 cell lysates
may inﬂuence RIP ubiquitination, we used bacterially ex-
pressed GST-fused forms of c-IAP2 as E3 for in vitro RIP
ubiquitination assays. Since GST proteins are known to in-
teract with each other, instead of GST-RIP, in vitro-synthe-
sized Flag-RIP was used as substrate. Under this assay
condition, we also tested whether c-IAP1 can mediate RIP
Fig. 5. c-IAP1 and c-IAP2 ubiquitinate RIP in vitro. (A) The c-IAP2
RING domain is required for RIP ubiquitination in vitro. Bacterially
expressed GST-RIP was incubated with Flag-c-IAP2 (indicated as C2)
or c-IAP2 without RING (C2DR) that were aﬃnity-puriﬁed from
transfected 293 cells, together with puriﬁed E1, E2 and His6-ubiquitin,
at 30 C for 60 min. After the reaction, the samples were resolved on
6% SDS–PAGE and analyzed by immunoblotting with anti-RIP Ab
(left). To examine self-ubiquitinating activity of c-IAP2, the same ly-
sates were probed with anti-c-IAP2 Ab (right). (B) c-IAP1 ubiquiti-
nates RIP as eﬃciently as c-IAP2. In vitro translated Flag-RIP was
incubated with the indicated bacterially expressed GST-fused proteins.
The reaction was performed in the same condition as written in panel
A. The reaction products were analyzed by immunoblotting with anti-
RIP Ab (left) and c-IAP2 Ab (right). Self-ubiquitinated products of
GST-c-IAP1 were not visualized with anti-c-IAP2 Ab.
Fig. 6. (A) RIP interacts weakly with c-IAP2 and this interaction is
enhanced in the presence of TRAF2. Bacterially expressed and puriﬁed
GST-C2 or GST-C2C were incubated with 293 cell lysates expressing
the indicated proteins, together with glutathione–Sepharose beads
under continuous shaking at 4 C for 4 h. The beads were washed
extensively and the interacting proteins were analyzed by immuno-
blotting with anti-RIP Ab (upper), anti-Flag Ab (middle) and anti-GST
Ab (lower). (B) TRAF2 has no eﬀect on c-IAP2-mediated RIP ubiq-
uitination.Flag-c-IAP2 and Flag-TRAF2, which were expressed in 293
cells, were puriﬁed in the bead-immobilized state and used for in vitro
ubiquitination reaction containing the substrate GST-RIP and other
components (E1, E2, His6-ubiquitin). After reaction at 30 C for 60
min, the samples were analyzed by immunoblotting with anti-RIP Ab
(left) and anti-c-IAP2 Ab (right).
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IAP2 mediated ubiquitination of Flag-RIP with similar eﬃ-
ciency, consistent with the observation that RIP was degraded
by c-IAP1 and c-IAP2 in vivo (left panel). When the same blot
was probed with anti-c-IAP2 Ab, self-ubiquitinated products
of GST-c-IAP2 were visualized, but those of GST-c-IAP1 were
not able to be seen due to no reactivity of anti-c-IAP2 Ab to
GST-c-IAP1 (right panel). These results suggest that c-IAP1
and c-IAP2 can promote RIP ubiquitination without the aid of
other cellular proteins originated from the transfected 293
cells.
3.6. TRAF2 promotes the interaction between c-IAP2 and RIP,
but has no eﬀect on c-IAP2-mediated RIP ubiquitination in
vitro
It has been shown that TRAF2 interacts with both c-IAP2
and RIP through its TRAF domain [5,7,9]. However, direct
association between RIP and c-IAP2 has not been reported.
Our observation that c-IAP2 induces the degradation of RIP
in vivo and ubiquitinates RIP directly in vitro suggests that a
close contact occurs between RIP and c-IAP2. Therefore, weexamined whether c-IAP2 interacts with RIP directly and
whether such interaction is inﬂuenced by TRAF2. Because
cotransfection of RIP and c-IAP2 in 293 cells results in the
degradation of RIP, study of physical association between RIP
and c-IAP2 was not feasible in these transfected cells. Thus, we
performed in vitro GST pull-down assay to examine the in-
teraction between these proteins in the presence or absence of
TRAF2 (Fig. 6A). Lysates of 293 cells expressing HA-RIP and
Flag-TRAF2 were incubated with GST-c-IAP2 or GST-C2C
together with glutathione–Sepharose beads at 4 C for 4 h. The
analysis of the complex pulled down by GST-c-IAP2 showed
that RIP and TRAF2 were found in this complex. Even in the
absence of TRAF2, RIP was pulled down by GST-c-IAP2 but
at a lesser amount compared to the reaction containing
TRAF2. Neither TRAF2 nor RIP was found in the complex
pulled-down by GST-C2C, indicating that both proteins in-
teract with c-IAP2 at the N terminal BIR domain of c-IAP2.
These results demonstrate that RIP and c-IAP2 interact
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TRAF2.
To examine whether TRAF2 per se can ubiquitinate RIP or
inﬂuence c-IAP2-mediated RIP ubiquitination, we performed
in vitro ubiquitination assays with puriﬁed TRAF2. Addition
of TRAF2 to the reaction neither ubiquitinated GST-RIP
(lane 3, Fig. 6B) nor aﬀected the c-IAP2-mediated ubiquiti-
nation of GST-RIP (compare lane 4 to lane 5). Although the
possibility that TRAF2 may require a diﬀerent E2 enzyme
instead of the UbcH5A that we tested cannot be ruled out, a
recent study has suggested that TRAF2 is not the E3 respon-
sible for the modiﬁcation of RIP [23], agreeing with our in
vitro result. In view of the property of TRAF2 to associate
with c-IAP2 and RIP, it may function as a bridging factor that
brings c-IAP2 and RIP into close proximity.
In conclusion, upon activation of TNFR1, RIP complexed
with TNFR1 is ubiquitinated only after translocating to the
cholesterol- and sphingolipid-enriched lipid rafts, whereas RIP
in the cytoplasmic compartment appeared not to undergo such
modiﬁcation [23]. Lipid rafts serve as platforms for RIP
modiﬁcation by recruiting molecules possessing E3 activity,
such as TRAF2 and c-IAPs. Our data suggest that c-IAPs can
function as E3 toward RIP. Whether such event occurs in the
context of TNFR1 complex in a stimulus-dependent manner
remains to be determined.
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